TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male or female patients aged \> 18 years.~* Patients with persistent asthma not optimally controlled (GINA 2010) on high doses of ICS or medium dose of ICS+LABA at a stable dose for at least 4 weeks prior to screening.~* Patients with FEV1 \>= 40% and \< 80% of predicted for the patient normal value and at least 0.9 L.~* Patients with a documented positive response to the reversibility test, defined as ΔFEV1 \>= 12% and \>= 200 mL over baseline, within 30 minutes after administration of 400 μg of salbutamol pMDI.~* At screening and at the end of the run-in period, patients with not adequately controlled asthma according to GINA 2010 and with score at the Asthma Control Questionnaire (ACQ)\> 0.75~Main Exclusion Criteria:~* History of near fatal asthma or of a past hospitalisation for asthma in Intensive Care Unit or of frequent exacerbations (3 or more asthma exacerbations/ year).~* Hospitalisation, Emergency Room admission or use of systemic steroids (more than 3 days) for asthma exacerbation in the 4 weeks prior to screening visit and during the run-in period.~* Symptomatic infection of the lower airways in the 4 weeks before the screening visit.~* Current or ex-smokers with total cumulative exposure equal or more than 5 pack-years and /or having stopped smoking one year or less prior to screening visit.~* Patients with a clinically significant abnormality at 12-lead ECG or presenting a QTcB interval value in ECG \> 450 msec in males or \> 470 msec in females).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHF 1535 200/6µg (Type: EXPERIMENTAL): None
- BDP 100µg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Europe-Africa Research Network for Evaluation of Second-line Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Previously documented HIV infection on at least one standard antibody-based test~* Age 12 years and above~* Taking 2NRTI + NNRTI-based regimen continuously for at least 12 months~* Naive to protease inhibitor therapy~* Good adherence to ART in the 12 weeks prior to screening defined as missing medication on no more than 3 days in the prior month~* Clinically stable and receiving treatment for any known opportunistic infections~* HIV treatment failure defined by one or more of clinical, immunological or virological criteria defined in the protocol, including VL and CD4 at screening visit~* Willing and able to give informed consent~* Able to attend for regular study follow up visits~Exclusion Criteria:~* Any major clinical contra-indications to the use of bPI, the NRTIs that are available to be selected for a second-line regimen or raltegravir~* Known Hepatitis B carrier (Hepatitis B surface antigen positive if tested)~* Requires concomitant medication with known major interactions with study drugs for which drug substitutions or dose alterations are not available or acceptable~* Women who are currently pregnant or breastfeeding~* Current participation in another clinical trial involving a treatment intervention (may be permitted in some circumstances, but must be discussed with MRC CTU)~* Life expectancy of less than one month in the opinion of the treating physician

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bPI + 2NRTIs (Type: ACTIVE_COMPARATOR): None
- bPI + raltegravir (Type: EXPERIMENTAL): None
- bPI monotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* no severe diarrhea no serious infection~Exclusion Criteria:~* serious diarrhea active,uncontrolled infection

- Gender: ALL
- Minimum Age: None
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- low-dose glucocorticoid (Type: EXPERIMENTAL): drug
- no intervention after transplant (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced or metastatic renal cell carcinoma.~Exclusion Criteria:~* No previous cytokines therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients treated with SUTENT® (Type: None): Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Ischemic Events in Patients With Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with PAD: ankle-brachial pressure index \<= 0.90~2. Controls: palpable pedal pulses, ankle-brachial pressure index 0.91-1.30~Exclusion Criteria:~1. Age \< 40 or \> 80 years at inclusion~2. Malignancy with a life expectancy \< 5 years~3. Atherothrombotic event within a month before inclusion (acute coronary syndrome, stroke or documented transient ischemic attack, critical limb ischemia)~4. pregnancy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- PAB (Type: None): Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =\< 0.90.
- Control (Type: None): Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Diagnosis of HCV-CV: must have all of the following~HCV infection documented by serology and/or plasma HCV RNA.~One or more organ system with objective evidence of active vasculitis such as:~Palpable purpura;~Glomerulonephritis (defined by the presence of glomerular hematuria and/or new or worsening proteinuria);~Acute peripheral neuropathy.~Detectable cryoglobulins and/or RF.~Failure of treatment with IFN-alpha and ribavirin to control manifestations of HCV-CV OR intolerance to IFN-alpha/ribavirin regimen.~Patients must have a personal physician responsible for the care of their HCV.~Ages of 18 and 75 years~Willingness to use effective contraception during and for 12 months following Rituximab treatment. Effective contraception methods include abstinence, surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap or sponge, or hormonal contraception.~EXCLUSION CRITERIA:~Recent (within 4 weeks) initiation of or increase in immunosuppressive therapy.~Active systemic infection (other than hepatitis C).~Pregnancy or breast feeding.~Prior treatment with Rituximab.~Known allergy to murine proteins.~Significant renal insufficiency (creatinine clearance less than 30 ml/min).~Presence of life-threatening HCV-CV; defined as rapidly progressive glomerulonephritis (defined as a doubling of the serum creatinine over a 3 month period), CNS vasculitis, cardiac disease due to active vasculitis, or GI vasculitis (defined by ischemic bowel, perforation, or infarction).~Significant hepatic insufficiency as manifested by Child-Pugh classification of B or C.~History of variceal bleeding, encephalopathy.~History of liver transplantation.~Co-infection with either HBV or HIV.~Any underlying medical condition that in the judgment of the investigator would put the patient at increased risk for serious infusion-related adverse events.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Immediate treatment (Type: OTHER): Patients receive treatment with four weekly infusions of rituximab 375mg/m2 immediately following randomization.
- Delayed treatment (Type: OTHER): Patients treated with standard therapy (corticosteroids, plasma exchange, etc.). After 6 months, they are eligibile to cross over and receive four weekly infusions of rituximab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In the run-in phase:~  * Standard surgery for fracture of the upper third of the femur, including femoral head and neck~* In the double-blind phase following the run-in phase:~  * Completion of the run-in phase without permanent treatment discontinuation~Exclusion Criteria:~* Any major orthopedic surgery within 3 months prior to enrolment;~* Deep vein thrombosis or pulmonary embolism within the last 12 months, or known post-phlebitic syndrome;~* High risk of bleeding;~* Known hypersensitivity to heparins;~* Any contraindication to the performance of venography;~* End stage renal disease or patient on dialysis~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semuloparin extension treatment (Type: EXPERIMENTAL): Extension treatment with Semuloparin sodium 20 mg (10 mg if SRI) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days.
- Placebo extension treatment (Type: PLACEBO_COMPARATOR): Extension treatment with placebo (for Semuloparin sodium) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be naive to emetogenic chemotherapy with histologically or cytologically confirmed malignant disease scheduled to receive a single dose of moderately emetogenic chemotherapy on study day 1~* Karnofsky score of 60 or greater~Exclusion Criteria:~* Patient is scheduled to receive any dose of cisplatin~* Patient will receive abdominal or pelvic radiation a week prior and up to 6 days after initiation of chemotherapy~* Any allergies to study drug or antiemetics~* Taking CYP3A4 substrates/prohibited medication~* Significant medical or mental conditions~* Abnormal laboratory values (platelets, absolute neutrophils, AST, ALT, bilirubin or creatinine).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
- 2 (Type: OTHER): Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pain Control After Cardiac Surgery Using Intravenous Acetaminophen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Males or females 18 years of age or older.~* Non-emergency cardiac surgery via a midline sternotomy at Cleveland Clinic Main Campus.~Exclusion Criteria:~1. Redo cardiac surgery.~2. Combined CABG (Coronary Artery Bypass Graft)\& valve replacement, multiple valve replacements, Ascending aortic or aortic arch surgery.~3. Weight \< 50 Kg or Body mass index \> 38 kg/m2.~4. Left ventricle EF ¡Ü 35% ,Right ventricular moderate or severe dysfunction.~5. Severe (3-4 +) Tricuspid Regurgitation.~6. Recent stroke (within 6 months).~7. Severe lung disease requiring home O2 therapy.~8. Preoperative renal insufficiency (Creatinine \> 2.0) or on dialysis.~9. History of liver cirrhosis or active liver disease.~10. Chronic pain conditions controlled by preoperative opioid administration.~11. Known allergy to acetaminophen or fentanyl.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV Acetaminophen (Type: EXPERIMENTAL): Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive up to four doses of IV placebo every six hours after surgery along with standard PCA (patient controlled) opioids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subarachnoid Block With Ultrasound-Guided Transversalis Fascia Plane Block for Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged between 18 and 45~* American Society of Anesthesiologists (ASA) physical score I or II~Exclusion Criteria:~* Patients who received general anesthesia~* hypersensitivity to the agents to be used~* body mass index (BMI) greater than 35 kg/m2~* coagulopathy~* local infections~* opioid addiction~* pregnancy-related hypertension or diabetes mellitus

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ultrasound guided transversalis fascia plane block (Type: ACTIVE_COMPARATOR): 20 mL of 0.25% bupivacaine
- ultrasound guided sham block (Type: PLACEBO_COMPARATOR): 20 mL of saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged 18 75, inclusive~* Established diagnosis of ulcerative colitis involving the sigmoid colon or proximal segments of bowel~* Total Mayo score between 5-12, inclusive, with endoscopic subscore of the Mayo score ≥ 2 and \> 15 cm of involvement beyond the anal verge~Exclusion Criteria:~* Women with a positive pregnancy test, who are breastfeeding, or who intend to become pregnant during the course of the study~* Diagnosis of Crohn's disease, microscopic colitis or indeterminate colitis~* Presence of ileostomy or colostomy, or history of prior colon resection~* Patients with planned hospitalization or surgery during the course of the study~* Known allergy to milk proteins, red meat or cornstarch~* Stools positive for enteric infection, including parasitic, or C. difficile toxin within 28 days of screening~* Documented presence of Hetatitis B (HBsAg), Hepatitis C (HCV), or HIV~* Presence of dysplasia of any grade on colonoscopic biopsies~* Treatment for cancer (excluding non-melanomatous cancer of the skin or cervical carcinoma in situ) or lymphoproliferative disorder (including lymphoma) within 5 years~* History of tuberculosis (TB) or Listeria infection, or known exposure to another person with active TB disease within 12 weeks of screening; or history of past or current infection with different opportunistic infections~* History of TNF inhibitor (infliximab, adalimumab or certolizumab pegol) use with primary treatment failure. Secondary treatment failures due to intolerance, allergic reaction, or loss of response will not constitute a basis for exclusion. Oral immunosuppressives, mesalamine, and corticosteroids (up to 20mg of prednisone per day) will be permitted so long as these medications are stable for defined periods of time before study participation commences.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AVX 470 (Type: ACTIVE_COMPARATOR): AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. 18-65 years old~2. Subject of childbearing potential must agree to use a consistent form of an acceptable double-barrier method of birth control.~3. Plasma HCV RNA ≥ 5 log10 IU/mL~4. HCV genotype 1~Exclusion criteria:~1. Received prior antiviral treatment for hepatitis C infection~2. Subject is pregnant or breastfeeding~3. Body Mass Index (BMI) \> 32~4. Currently abusing alcohol or illicit drugs~5. Currently receiving methadone, buprenorphine or other drugs for the treatment of opioid addiction~6. Co-infected with hepatitis B virus (HBV, HBsAg positive) and/or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Subjects randomized 8:2 (active:placebo) to receive one 25 milligrams (mg) capsule of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
- Cohort B (Type: EXPERIMENTAL): Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
- Cohort C (Type: EXPERIMENTAL): Subjects randomized 8:2 (active:placebo) to receive three 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
- Cohort D (Type: EXPERIMENTAL): Subjects randomized 8:2 (active:placebo) to receive four 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete